Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesHUTCHMED China Ltd

HUTCHMED China Ltd

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
208.0 GBX -2.00 ( 0.95%)
Last update at 2026-10-27T16:35:00Z
VOLUME
13059
Market Cap
1847.96M
P/E
5.38

Momentum Score

…

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
206.00
Low
219.00
High
52 Week Price Range
190.97
Low
292.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
210.00
Dividend Yield
-
Revenue TTM
548.51M
Revenue Per Share
0.64
Gross Profit TTM
63.87M
Debt / Equity
0.08
ROE
45.25%
Net Debt
26.53M
ROCE
-3.80%
Diluted EPS TTM
0.40

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 521.47M 45.36M 105.60M -410.42M -215.74M
Minority interest -0.82M -0.44M -0.31M -0.45M -27.61M
Net income 457.02M 37.73M 100.78M -410.14M -227.66M
Selling general administrative 103.03M 64.30M 79.78M 92.17M 89.30M
Selling and marketing expenses - 48.62M 53.39M 43.93M 37.83M
Gross profit 212.22M 281.32M 151.55M 115.31M 97.89M
Reconciled depreciation 13.31M 12.34M 8.21M 8.66M 7.19M
Ebit -54.59M 1.76M 59.07M -409.77M -336.46M
Ebitda -41.28M 14.11M 67.27M -401.11M -329.27M
Depreciation and amortization 13.31M 12.34M 8.21M 8.66M 7.19M
Operating income -54.59M -40.61M 18.38M -409.77M -336.46M
Other operating expenses 603.24M 670.81M 819.62M 834.10M 684.45M
Interest expense 2.87M 2.87M 0.76M 0.65M 0.59M
Tax provision 63.61M 7.19M 4.51M -0.28M 11.92M
Interest income 49.88M 40.08M 36.15M 9.60M 2.08M
Net interest income 47.01M 37.21M 35.39M 8.95M 1.48M
Income tax expense 63.63M 7.19M 4.51M -0.28M 11.92M
Total revenue 548.65M 630.20M 838.00M 426.41M 356.13M
Total operating expenses 266.81M 321.93M 133.18M 523.00M 426.21M
Cost of revenue 336.43M 348.88M 686.45M 311.10M 258.23M
Total other income expense net 576.06M 39.50M 87.23M -0.65M 120.72M
Net income from continuing ops 457.73M 38.17M 101.09M -360.39M -167.04M
Net income applicable to common shares - - - -360.83M -194.65M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1750.71M 1274.20M 1279.77M 1029.44M 1372.66M
Intangible assets 8.93M 167.74M 116.89M - 0.16M
Other current assets 11.10M 12.30M 43.35M 152.20M 164.62M
Total liab 501.15M 502.34M 536.39M 392.57M 333.15M
Total stockholder equity 1236.24M 759.93M 730.54M 610.37M 986.89M
Other current liab 210.69M 306.19M 329.04M 282.79M 17.19M
Common stock 87.11M 87.16M 87.13M 86.48M 86.45M
Capital stock 87.23M 87.16M 87.13M 86.48M 86.45M
Retained earnings -378.13M -833.17M -870.87M -971.48M -610.33M
Other liab - - - 15.37M 14.33M
Good will 3.11M 2.99M - - 3.38M
Other assets - - - 31.11M 27.41M
Cash 71.23M 153.96M 283.59M 313.28M 377.54M
Total current liabilities 315.34M 376.56M 403.03M 353.90M 311.66M
Current deferred revenue 31.37M - - - 226.38M
Net debt 26.53M -64.14M -197.46M -289.98M -343.48M
Short term debt 27.81M 26.30M 35.08M - 26.91M
Short long term debt 24.97M 23.37M 31.16M 0.00M 26.91M
Short long term debt total 97.76M 89.82M 86.13M 23.30M 34.07M
Other stockholder equity 1531.78M 1517.53M 1514.28M 1495.37M 1510.77M
Property plant equipment - - - 84.67M 53.15M
Total current assets 1565.20M 1066.56M 1096.84M 839.89M 1212.08M
Net tangible assets - - - 610.37M 983.35M
Short term investments 1294.18M 682.15M 602.75M 317.72M 634.16M
Net receivables 147.63M 167.74M 116.89M 97.99M 147.73M
Long term debt 68.19M 59.43M 48.19M 18.10M 0.00M
Inventory 41.07M 50.40M 50.26M 56.69M 35.76M
Accounts payable 45.47M 42.52M 36.33M 71.11M 41.18M
Accumulated other comprehensive income -4.53M -11.59M -8.16M - -
Non currrent assets other 11.14M 697.59M 30.13M 333.46M 639.00M
Non current assets total 185.50M 207.64M 182.93M 189.56M 160.59M
Capital lease obligations 4.73M 7.01M 6.79M 5.20M 7.16M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -613.79M -96.06M -291.14M 296.59M -275.49M
Change to liabilities - - - 30.32M 20.64M
Total cashflows from investing activities -29.42M -96.06M -291.14M 296.59M -306.32M
Net borrowings 6.26M 5.61M 61.70M -9.17M -0.58M
Total cash from financing activities 7.84M -30.67M 48.66M -82.76M 650.03M
Change to operating activities - - - 64.04M 63.46M
Net income 457.02M 38.17M 101.09M -360.39M -167.04M
Change in cash -94.28M -129.63M -29.69M -64.26M 141.91M
Begin period cash flow 165.51M 283.59M 313.28M 377.54M 235.63M
End period cash flow 71.23M 153.96M 283.59M 313.28M 377.54M
Total cash from operating activities -64.67M 0.50M 219.26M -268.60M -204.22M
Issuance of capital stock 1.58M 0.79M 5.09M 0.17M 717.32M
Depreciation 13.31M 12.34M 8.21M 8.66M 7.19M
Other cashflows from investing activities - 1.28M 29.50M - -15.00M
Change to inventory 9.54M -0.77M 4.13M -21.21M -16.00M
Change to account receivables 28.87M -41.57M -21.34M -14.45M -35.63M
Sale purchase of stock 0.00M -36.06M -9.07M -48.08M -27.31M
Other cashflows from financing activities - -1.00M -9.07M -7.93M -39.98M
Change to netincome - - - 24.85M -49.27M
Capital expenditures 14.15M 17.93M 32.61M 36.66M 16.76M
Change in working capital -60.88M -62.17M 71.15M 58.70M 32.46M
Stock based compensation 15.29M 21.61M 36.60M 30.59M 41.99M
Other non cash items -474.13M -9.45M 1.60M -6.17M -3.68M
Free cash flow -78.82M -17.44M 186.65M -305.26M -220.98M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
HCM
HUTCHMED China Ltd		 -2.00
0.95%		 208.00 5.38 19.30 3.37 2.02 2.25 2.40
HLN
Haleon PLC		 -4.20
1.10%		 376.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 4.00
0.24%		 1704.00 9.73 9.03 0.85 1.45 1.53 6.07
AGY
Allergy Therapeutics		 -
-%		 4.25 - 106.38 11.72 159.47 12.12 -4.15
STX
Shield Therapeutics plc		 -0.17
3.09%		 5.33 - 65.36 2.24 76.33 3.34 -1.49

Profile*

HUTCHMED China Ltd

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Cheung Kong Center, Hong Kong, Hong Kong

852 2121 8200

https://www.hutch-med.com

1796

Name Title Year Born
Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA Exec. Chairman 1952
Dr. Weiguo Su B.Sc., Ph.D. CEO, Chief Scientific Officer & Exec. Director 1957
Mr. Chig Fung Cheng BEc, CA CFO & Exec. Director 1967
Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito Company Sec. & Non-Exec. Director 1952
Dr. Karen Jane Atkin Exec. VP & COO 1966
Mr. Kin Hung Lee M.B.A. Sr. VP of Corp. Fin. & Devel. 1977
Mr. Charles George Rupert Nixon Group Gen. Counsel 1970
Ms. Selina Zhang Sr. VP of Global HR NA
Dr. Qingmei Wang Ph.D. Sr. VP of Bus. Devel. & Strategic Alliances 1963
Mr. Hong Chen Sr. VP & Chief Commercial Officer- China 1970

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

No data available
No data available

Equity Sectors*

  • Basic Materials

    -2.34%

  • Communication Services

    +0.74%

  • Consumer Cyclical

    -2.81%

  • Consumer Defensive

    -0.87%

  • Energy

    -3.16%

  • Financial Services

    -2.32%

  • Healthcare

    -0.53%

  • Industrials

    -4.40%

  • Real Estate

    -0.43%

  • Technology

    -4.09%

  • Utilities

    -1.03%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…